Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RV568 in seasonal allergic rhinitis
NCT01230619Phase 2Completed
- Sponsor
- RespiVert
- Start
- Oct 2010
- Primary completion
- Nov 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial in seasonal allergic rhinitis (SAR) comparing RV568 treatment group with Placebo treatment group (2 arms). Primary endpoint: Total Nasal Symptom Score at 2 days. Started Oct 2010; status: completed.
02
Drugs
RV568
03
Conditions
seasonal allergic rhinitis (SAR)
Beyond the preview
Go deeper on NCT01230619.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01230619.